• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Genenta Science S.p.A.

    3/29/24 4:45:24 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GNTA alert in real time by email
    S-8 1 forms-8.htm

     

    As filed with the Securities and Exchange Commission on March 29, 2024

     

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    GENENTA SCIENCE S.P.A.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Republic of Italy   Not Applicable

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

     

     

     

    Pierluigi Paracchi
    Chief Executive Officer
    Via Olgettina No. 58
    20132 Milan, Italy
    Tel: +39-02-2643-4681

    (Address, including zip code, and telephone number of principal executive offices)

     

     

     

    2021 – 2025 Stock Option Plan

    (Full title of the plan)

     

     

     

    Cogency Global Inc.
    122 East 42nd Street, 18th Floor
    New York, New York 10168
    Tel: +1.800.221.0102

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

     

    Copies to:

    Per B. Chilstrom, Esq.

    Fenwick & West LLP

    902 Broadway

    New York, New York 10010

    (212) 430-2600

     

     

     

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
           
    Non-accelerated filer ☒ Smaller reporting company ☐
           
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 relates to the registration of ordinary shares with no par value per share of Genenta Science S.p.A. (the “Registrant”) issuable under the Registrant’s 2021 – 2025 Stock Option Plan (the “Plan”). The ordinary shares may be represented by American depositary shares (“ADSs”), each representing one ordinary share. ADSs issuable upon deposit of the ordinary shares registered hereby have been registered pursuant to a separate registration statement on Form F-6 (File No. 333-261223).

     

     

     

     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information specified in Part I of Form S-8 is omitted from this filing in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), and the instructions to Form S-8. The documents containing the information specified in Part I will be delivered to the participants of the Plan as required by Rule 428(b)(1) under the Securities Act, and such documents are not being filed with the Securities and Exchange Commission (the “Commission”) either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act.

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference

     

    The following documents filed by the Registrant with the Commission pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference:

     

      ● the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2023 filed with the Commission on March 29, 2024; and

     

      ● the descriptions of the Registrant’s ordinary shares and ADSs contained in Exhibit 2.4 to its Annual Report on Form 20-F for the year ended December 31, 2021 filed by the Registrant with the Commission on March May 2, 2022, including any amendment or report filed to update such description and any subsequent amendments or reports filed for the purpose of updating such description.

     

    All documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of the filing of such documents, except that, unless expressly incorporated by reference, any information provided in documents that is furnished (rather than filed) or is otherwise not deemed to be filed under applicable Commission rules shall not be deemed to be incorporated by reference in this Registration Statement.

     

    Any statement contained herein or in a document incorporated or deemed to be incorporated by reference in this Registration Statement shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration Statement, or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this Registration Statement, modifies or supersedes such earlier statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     

     

     

    Item 4. Description of Securities

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel

     

    None.

     

    Item 6. Indemnification of Directors and Officers

     

    Italian law requires directors and members of any committee designated by the board of directors to perform their duties with the degree of diligence required by the nature of their office and according to their specific level of competence. Liability should never arise from business judgments under the circumstances, even if the decisions made entail significant economic risks, but be attributable only to lack of diligence by the director in appreciating in advance the risk involved in the transaction to be undertaken, and therefore, the omission of possible precautions, assessments or the lack of information normally required for a decision of that type, taken under those circumstances and in that manner. Directors are liable to the company’s creditors when their improper management conduct impairs the company’s assets and prevents the company from satisfying creditors’ claims. If the company cannot repay its creditors, and a court determines that the directors did not adequately perform their duties relating to the preservation of assets, the court may find directors liable.

     

    In order to provide enhanced liability protection for its directors and to attract and retain highly qualified individuals to act as directors, the Registrant’s board of directors has agreed to indemnify each current and future member of the board of directors to the maximum extent permitted by law, save for a limited number of instances, including when (i) officers and directors’ acts or omissions constituted willful misconduct or gross negligence, (ii) officers and directors did not act in good faith, for a purpose which they reasonably believed to be in, or not opposed to, the best interests of the Registrant and (iii) officers and directors are held liable towards the Registrant.

     

    Item 7. Exemption from Registration Claimed

     

    Not applicable.

     

    Item 8. Exhibits

     

    See the Index to Exhibits attached hereto.

     

    Item 9. Undertakings

     

    (a) The undersigned Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) To include any prospectus required by section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;

     

     

     

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the registration statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference herein.

     

    (2) That for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to section 13(a) or section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    INDEX TO EXHIBITS

     

    Exhibit

    Number

      Description of Exhibit
         
    3.1   Deed of Incorporation of Genenta Science S.p.A. (incorporated by reference to Exhibit 3.1 to the Registrant’s Registration Statement on Form F-1 (File No. 333-260923))
         
    3.2   Amended and Restated Bylaws of Genenta Science S.p.A. (incorporated by reference to Exhibit 3.2 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2022)
         
    4.1   Deposit Agreement dated December 17, 2021 between the Registrant and The Bank of New York Mellon, as depositary (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form F-1 (File No. 333-260923))
         
    4.2   Form of American Depositary Receipt (included in Exhibit 4.1)
         
    5.1*   Opinion of Giovanelli and Associates, Italian counsel to the Registrant
         
    10.1   Genenta Science S.p.A. 2021 – 2025 Stock Option Plan (incorporated by reference to Exhibit 10.8 to the Registrant’s Registration Statement on Form F-1 (File No. 333-260923))
         
    23.1*   Consent of Dannible & McKee, LLP.
         
    23.2*   Consent of Giovanelli and Associates (included in Exhibit 5.1)
         
    24.1   Powers of Attorney (included on the signature page)
         
    107*   Filing Fee Table

     

     

     

    * Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Milan, Italy on the 29th day of March, 2024.

     

      GENENTA SCIENCE S.P.A.
         
      By:

    /s/ Pierluigi Paracchi

      Name: Pierluigi Paracchi
      Title: Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Pierluigi Paracchi and Richard Slansky, and each of them, as his or her true and lawful attorneys-in-fact, proxies and agents, each with full power of substitution and resubstitution and full power to act without the other, for him or her in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule 462(b) increasing the number of securities for which registration is sought), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact, proxies and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, proxies and agents, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

     

      Signatures   Title   Date
               
    By: /s/ Pierluigi Paracchi   Chief Executive Officer   March 29, 2024
      Pierluigi Paracchi   (Principal Executive Officer)    
               
    By: /s/ Richard B. Slansky   Chief Financial Officer   March 29, 2024
      Richard B. Slansky   (Principal Financial Officer and Principal Accounting Officer)    
               
    By: /s/ Mark Sirgo   Chairman of the Board and Director   March 29, 2024
      Mark Sirgo        
               
    By: /s/ Roger Abravanel   Director   March 29, 2024
      Roger Abravanel        
               
    By: /s/ Guido Guidi   Director   March 29, 2024
      Guido Guidi        
               
    By: /s/ Anthony Marucci   Director   March 29, 2024
      Anthony Marucci        

     

     

     

     

    SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

     

    Pursuant to the Securities Act, the undersigned, Cogency Global Inc., the duly authorized representative in the United States of Genenta Science S.p.A., has signed this Registration Statement on March 29, 2024.

     

      Cogency Global Inc.
      Authorized U.S. Representative
         
      By: /s/ Colleen A. De Vries
      Name: Colleen A. De Vries
      Title: Senior Vice-President on behalf of Cogency Global Inc.

     

     

     

    Get the next $GNTA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GNTA

    DatePrice TargetRatingAnalyst
    6/29/2023$15.00Buy
    ROTH MKM
    7/25/2022$25.00Buy
    H.C. Wainwright
    More analyst ratings

    $GNTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator

    Building on Biotech Heritage, Expanding into Defense and National Security Through Industrial Integrations of Privately Held Specialized Italian CompaniesATC - a Defense-Sector Company: First Industrial IntegrationPraexidia Foundation Joins as a Long-Term Strategic ShareholderCorporate Name Change to Saentra Forge S.p.A.Biotech Clinical Updates and Partnering StrategyCash, Cash Equivalents, and Marketable Securities of approx. $33 million MILAN and NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- In response to evolving market dynamics and strategic opportunities, Genenta Science S.p.A (NASDAQ:GNTA) is embarking on a strategic transformation to evolve into a next-generation strategic industr

    1/27/26 3:00:00 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Genenta Science Provides Update on CEO Ownership

    MILAN and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage gene-therapy company developing hematopoietic stem-cell-based immunotherapies for solid tumors, provides an update regarding the ownership position of its Chief Executive Officer and Co-Founder, Pierluigi Paracchi. Over time, Mr. Paracchi has acquired 30,000 American Depositary Shares ("ADSs") of the Company in total through open-market purchases. As reported in the Company's filings with the U.S. Securities and Exchange Commission ("SEC"), Mr. Paracchi's transactions in the Company's securities have consisted of open-market purchases, with no reported sales. As calculated in accordance

    12/19/25 2:30:00 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial

    MILAN, Italy and NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage biotechnology company developing a cell-based platform for targeted delivery of therapeutic payloads in oncology, today announced an update from its ongoing TEM-GBM study in newly diagnosed glioblastoma multiforme (GBM) patients with an unmethylated MGMT (uMGMT) gene promoter. As of the November 21, 2025 data cut, 25 patients have been treated with Temferon. These data1 are compared to the previously disclosed April 15, 2025 cut, communicated on July 1, 2025. More than seven months after the prior update, key survival metrics for the TEM-GBM patients remain consistent. 44% of pati

    11/24/25 4:00:00 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GNTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM resumed coverage on Genenta S.p.A. with a new price target

    ROTH MKM resumed coverage of Genenta S.p.A. with a rating of Buy and set a new price target of $15.00

    6/29/23 9:11:48 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Genenta S.p.A. with a new price target

    H.C. Wainwright initiated coverage of Genenta S.p.A. with a rating of Buy and set a new price target of $25.00

    7/25/22 7:15:53 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GNTA
    SEC Filings

    View All

    SEC Form 424B5 filed by Genenta Science S.p.A.

    424B5 - Genenta Science S.p.A. (0001838716) (Filer)

    1/27/26 6:10:58 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Genenta Science S.p.A.

    6-K - Genenta Science S.p.A. (0001838716) (Filer)

    1/27/26 6:05:38 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Genenta Science S.p.A.

    6-K - Genenta Science S.p.A. (0001838716) (Filer)

    1/27/26 6:03:51 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GNTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Genenta Science S.p.A. (Amendment)

    SC 13G/A - Genenta Science S.p.A. (0001838716) (Subject)

    2/12/24 4:05:34 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Genenta Science S.p.A. (Amendment)

    SC 13G/A - Genenta Science S.p.A. (0001838716) (Subject)

    2/10/23 6:02:50 AM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Genenta Science S.p.A.

    SC 13G - Genenta Science S.p.A. (0001838716) (Subject)

    2/25/22 1:17:49 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GNTA
    Leadership Updates

    Live Leadership Updates

    View All

    ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

    Event showcases Italy as leading competitive hub for investments in biotech, healthcare, medical devices, and pharmaceuticals, and includes experts discussing private and public/institutional financial opportunities in the €270 Billion Italian life sciences sector1 SAN FRANCISCO, Jan. 8, 2025 /PRNewswire/ -- To promote investment opportunities in Italy in 2025, the Italian Trade Agency (ITA) and the Ministry of Foreign Affairs and International Cooperation will be hosting the eighth edition of "Italy on the Move," a side event of the 43rd annual J.P. Morgan Healthcare Conference 2025. The event will take place at INNOVIT (710 Sansome Street), San Francisco's Italian Innovation and Culture Hu

    1/8/25 3:17:00 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

    MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and

    5/6/24 6:25:00 AM ET
    $ARYD
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Corium Pharma Solutions Appoints Mark Sirgo as Chief Executive Officer

    Corium Pharma Solutions, Inc. ("Corium Pharma Solutions" or "CPSI"), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors. Dr. Sirgo is a pharmaceutical executive with over 35 years' experience in the industry, including founding and serving as the President, Chief Executive Officer, and Vice Chairman of BioDelivery Sciences International, Inc. ("BDSI"), a commercial-stage specialty pharmaceutical company focused on pain and addiction management. During his tenure at BDSI,

    1/17/23 8:00:00 AM ET
    $AGRX
    $GNTA
    $NMTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Package Goods/Cosmetics